跳至主要内容
临床试验/NCT03685773
NCT03685773撤回2 期

The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

Albert Einstein College of Medicine1 个研究点 分布在 1 个国家开始时间: 2019年4月21日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
试验地点
1
主要终点
Endogenous glucose production (EGP)

研究概览

简要总结

It is believed that important brain centers send signals through the vagus nerve to the liver to suppress the amount of glucose (sugar) that gets produced. People who have received liver transplants have had their vagus nerve cut during transplantation, and many of these individuals have diabetes at one year post-transplant. The goals of this study are: to see whether metabolic control centers in the brain can still be activated normally with the medication diazoxide in patients who have had a liver transplant, and to understand whether disrupting the vagus nerve would result in excess glucose being produced by the liver (ie. a potential mechanism for why these patients develop diabetes).

详细描述

In this study, investigators will study both diabetic and non-diabetic individuals who are otherwise healthy more than one year after receiving a liver transplant. They will participate in at least one of the following two parts of this study: The first involves functional magnetic resonance imaging (fMRI), and the second is using a day-long infusion study called a "pancreatic clamp."

Functional magnetic resonance imaging (fMRI) is a technique for measuring and mapping brain activity that is noninvasive and safe. This technique relies on the fact that blood flow in the brain and the activity of brain cells are coupled. Investigators will observe the activity of metabolically-relevant areas of the brain by activating potassium channels with diazoxide at baseline and at 2-hour intervals vs when given placebo.

In the pancreatic clamp study, glucose (a sugar) and insulin (a hormone produced in the pancreas that regulates the amount of sugar in the blood) are infused with an intravenous catheter. Blood samples are collected periodically throughout the procedure to measure blood sugar levels and the levels of several hormones that are found in the body which are related to glucose metabolism. The rates of endogenous glucose production (a measure of the body's production of sugar) will be measured as the main measurement of the study.

All participants will be screened prior to study enrollment. For the fMRI studies, eligible participants will come on two separate occasions for day-long study visits (one day in which the brain will be imaged before and after receiving diazoxide (a potassium channel activator), and one day in which the brain will be imaged before and after placebo. For the pancreatic clamp studies, eligible participants will come on two separate occasions for day-long study visits (one study with diazoxide, and one study with placebo). All studies in participants with type 2 diabetes will include overnight admissions prior to the study day for gradual normalizing of blood glucose through the infusion of insulin. Participants without diabetes will not have to stay for an overnight admission. Study participants with type 2 diabetes will also be eligible for an additional study in which Nicotinic Acid will be infused overnight to lower free fatty acid (FFA) levels. It will be determined whether FFA lowering will impact the fMRI studies and clamp studies that will be performed the next day.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Single (Participant)

盲法说明

The subject will be blinded to which study drug is received first (Drug or Placebo).

入排标准

年龄范围
21 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Liver Transplant at least one year ago
  • Age: 21-70

排除标准

  • BP > 150/90 or <90/60 on more than one occasion, unless there is a documented history of white coat hypertension by treating physician.
  • Triglycerides > 400 mg/dl and/or Total Cholesterol >300 mg/dl
  • Clinically significant liver dysfunction
  • Clinically significant kidney dysfunction, GFR: <60 mg/dL
  • Anemia: HgB <12.5 for men and <11.0 for women
  • Positive urine drug test. Occasional use of cannabis (once or twice per week) will not be a basis for exclusion.
  • Urinalysis: Clinically significant abnormalities
  • Clinically significant electrolyte abnormalities
  • Smoking >10 cig/day
  • Alcohol: Men >14 drinks/wk or >4 drinks/day, Women >7 drinks/wk or >3 drinks/day
  • History of active hepatitis infection, HIV/AIDS, chronic kidney disease (stage 3 or greater), active cancer, cardiovascular disease or other heart disease, systemic rheumatologic conditions, seizures, bleeding disorders, muscle disease
  • Surgeries that involve removal of endocrine glands except for thyroidectomy (if euthyroid on thyroid hormone replacement - if such history T4 and TSH will be checked)
  • Pregnant women
  • Subject enrolled in another study less than one month prior to the anticipated start date in the proposed study, besides those done by our group
  • Family history: family history of premature cardiac death
  • Allergies to medication administered during study
  • Uncontrolled psychiatric disorders
  • Any condition which in the opinion of the PI makes the subject ill-suited for participation in the study

研究组 & 干预措施

MRI: Non-diabetic transplant (Diazoxide)

Experimental

Diazoxide (up to 7 mg/kg)

干预措施: Diazoxide (Drug)

MRI: Non-diabetic transplant (Placebo)

Placebo Comparator

Taste-matched placebo for diazoxide

干预措施: Placebo (for diazoxide) (Drug)

MRI: T2D transplant (Diazoxide)

Experimental

Diazoxide (up to 7 mg/kg)

干预措施: Diazoxide (Drug)

MRI: T2D transplant (Placebo)

Placebo Comparator

Taste-matched placebo for diazoxide

干预措施: Placebo (for diazoxide) (Drug)

Clamp: Non-diabetic transplant (Diazoxide)

Experimental

Diazoxide (up to 7 mg/kg) before pancreatic clamp study

干预措施: Diazoxide (Drug)

Clamp: Non-diabetic transplant (Placebo)

Placebo Comparator

Taste-matched placebo (for diazoxide) before pancreatic clamp study

干预措施: Placebo (for diazoxide) (Drug)

Clamp: T2D transplant (Diazoxide)

Experimental

Diazoxide (up to 7 mg/kg) before pancreatic clamp study

干预措施: Diazoxide (Drug)

Clamp: T2D transplant (Placebo)

Placebo Comparator

Taste-matched placebo (for diazoxide) before pancreatic clamp study

干预措施: Placebo (for diazoxide) (Drug)

Clamp: T2D transplant (Diazoxide + Nicotinic Acid)

Experimental

Nicotinic acid infusion and diazoxide (up to 7 mg/kg) before pancreatic clamp study

干预措施: Diazoxide (Drug)

Clamp: T2D transplant (Diazoxide + Nicotinic Acid)

Experimental

Nicotinic acid infusion and diazoxide (up to 7 mg/kg) before pancreatic clamp study

干预措施: Nicotinic acid (Drug)

Clamp: T2D transplant (Placebo + Nicotinic Acid)

Experimental

Nicotinic acid infusion and placebo (for diazoxide) before pancreatic clamp study

干预措施: Placebo (for diazoxide) (Drug)

Clamp: T2D transplant (Placebo + Nicotinic Acid)

Experimental

Nicotinic acid infusion and placebo (for diazoxide) before pancreatic clamp study

干预措施: Nicotinic acid (Drug)

MRI: T2D transplant (Diazoxide + Nicotinic Acid)

Experimental

Nicotinic acid infusion and diazoxide (up to 7 mg/kg)

干预措施: Diazoxide (Drug)

MRI: T2D transplant (Diazoxide + Nicotinic Acid)

Experimental

Nicotinic acid infusion and diazoxide (up to 7 mg/kg)

干预措施: Nicotinic acid (Drug)

MRI: T2D transplant (Placebo + Nicotinic Acid)

Experimental

Nicotinic acid infusion and placebo (for diazoxide)

干预措施: Placebo (for diazoxide) (Drug)

MRI: T2D transplant (Placebo + Nicotinic Acid)

Experimental

Nicotinic acid infusion and placebo (for diazoxide)

干预措施: Nicotinic acid (Drug)

结局指标

主要结局

Endogenous glucose production (EGP)

时间窗: 7-7.5 hours

Rates of EGP (a measure of the body's production of sugar) will be measured during pancreatic clamp studies, with suppression of pancreatic hormones by somatostatin infusion and basal hormone replacement.

次要结局

  • Change in Arterial Spin Labeling (ASL) signal(Baseline, 2 hours post dosing, 4 hours post dosing)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验